7EK6
Structure of viral peptides IPB19/N52
Summary for 7EK6
Entry DOI | 10.2210/pdb7ek6/pdb |
Descriptor | Spike protein S2 (3 entities in total) |
Functional Keywords | sars-cov-2, spike protein, membrane fusion, fusion inhibitor, lipopeptide, viral protein |
Biological source | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2) More |
Total number of polymer chains | 2 |
Total formula weight | 9907.04 |
Authors | |
Primary citation | Yu, D.,Zhu, Y.,Jiao, T.,Wu, T.,Xiao, X.,Qin, B.,Chong, H.,Lei, X.,Ren, L.,Cui, S.,Wang, J.,He, Y. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg Microbes Infect, 10:1227-1240, 2021 Cited by PubMed Abstract: The ongoing pandemic of COVID-19, caused by SARS-CoV-2, has severely impacted the global public health and socio-economic stability, calling for effective vaccines and therapeutics. In this study, we continued our efforts to develop more efficient SARS-CoV-2 fusion inhibitors and achieved significant findings. First, we found that the membrane-proximal external region (MPER) sequence of SARS-CoV-2 spike fusion protein plays a critical role in viral infectivity and can serve as an ideal template for design of fusion-inhibitory peptides. Second, a panel of novel lipopeptides was generated with greatly improved activity in inhibiting SARS-CoV-2 fusion and infection. Third, we showed that the new inhibitors maintained the potent inhibitory activity against emerging SARS-CoV-2 variants, including those with the major mutations of the B.1.1.7 and B.1.351 strains circulating in the United Kingdom and South Africa, respectively. Fourth, the new inhibitors also cross-inhibited other human CoVs, including SARS-CoV, MERS-CoV, HCoV-229E, and HCoV-NL63. Fifth, the structural properties of the new inhibitors were characterized by circular dichroism (CD) spectroscopy and crystallographic approach, which revealed the mechanisms underlying the high binding and inhibition. Combined, our studies provide important information for understanding the mechanism of SARS-CoV-2 fusion and a framework for the development of peptide therapeutics for the treatment of SARS-CoV-2 and other CoVs. PubMed: 34057039DOI: 10.1080/22221751.2021.1937329 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.243 Å) |
Structure validation
Download full validation report
